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Abstract Background: Matrix-metalloproteinases (MMPs) and their inhibitors, the tissue inhibitors of metalloprotei-
nases (TIMPs), are involved in the turnover of extracellularmatrix.Chronic obstructive pulmonary disease (COPD) and
idiopathic pulmonary fibrosis (IPF) are inflammatory diseases characterized by excessivematrix degradation and tissue
fibrosis.We have compared sputum concentrations of MMP-9,TIMP-1and the controlling cytokine tumor necrosis factor
(TNF)-alphainpatientswithCOPD,IPFandhealthysubjects.Methods:In a cross-sectional analysis,12 patientswith stable
COPD,15 patientswith IPFand14 healthy subjects underwent sputuminduction.Induced sputumcellswere counted and
concentrations of MMP-9,TIMP-1and TNF weremeasured by enzyme immunoassays. Results: Sputumneutrophilswere
markedly elevated in COPD and IPF patients compared with controls (Po0.001, both comparisons).Concentrations of
MMP-9 andtheMMP-9:TIMP-1ratiowereincreasedinCOPD (Po0.001vs.IPFandcontrols), whereas sputumTIMP-1levels
were both elevated in COPDand IPF (Po0.01vs. controls, both comparisons).TNFlevelswere similar in all three groups
(P40.2, all comparisons). MMP-9 concentrations were negatively correlated with airway obstruction (FEV1%FVC) in
COPD (rho=0.62, P=0.03), but not with diffusion capacity or vital capacity (% predicted) in IPF (rho=0.06, P=0.85,
and rho=0.3, P=0.29, respectively).MMP-9 was positively correlatedwith sputumneutrophils in all patients (rho=0.68,
Po0.0001), and withTNF in COPD patients (rho=0.76, P=0.004).Conclusions:These data underline the significance of
protease/antiprotease imbalance for the pathogenesis of inflammatory lung diseases.Despite similar cellular inflamma-
tory patterns both in COPD and IPF sputa, marked differences were observed with regard to MMP-9:TIMP-1 balance.
r 2003 Elsevier Science Ltd.Allrights reserved.
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Matrix-metalloproteinases (MMPs) are crucial for home-
ostasis and turnover of the extracellularmatrix in health
and disease.Three subclasses of MMPs, gelatinases, col-
lagenases and stromelysines, have been identi¢ed until
now, each of them di¡ering in tissue expression and sub-
strate speci¢ty (1).Besidesmacrophages, eosinophils and
epithelial cells, neutrophils are a major source of MMPs
(2,3).MMP-9 is involved in tumor invasion andmetastasis
(4), but also plays a major role in chronic in£ammatoryReceived 30 July 2002, Revised1October 2002, accepted 4 November
2002
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sion and activation is controlled by a variety of media-
tors, e.g. cytokines like tumour necrosis factor (TNF)-
alpha (6^8). Several lines of evidence also suggest a con-
tribution of MMP-9 to chronic irreversible airway nar-
rowing as observed in chronic obstructive pulmonary
disease (COPD) or uncontrolled asthmatics with airway
‘‘remodeling’’ (9).
MMP activity is physiologically controlled by a class of
protein inhibitors called tissue inhibitors of metallopro-
teinases (TIMP). MMP-9 and its inhibitor, TIMP-1, have
been detected in serum (10) and sputum (11) samples
of asthmatics, and their concentration and molar
MMP-9:TIMP-1 ratio correlated with clinical parameters
and lung function.
Chronic obstructive pulmonary disease (COPD)
is a debilitating in£ammatory disease of the lungs
MOLARRATIOOFMMPS,TIMPS INHEALTHYANDPATIENTSWITHPULMONARYDISEASE 635characterized by an increased presence of neutrophils
and macrophages in the airways of a¡ected patients
(12,13).Neutrophils produceproin£ammatorymediators,
cytokines and proteases, and neutrophilic in£ammation
eventually leads to matrix degradation and the develop-
ment of emphysema (14^17).
Idiopathic pulmonary ¢brosis (IPF) is a chronic in£am-
matory disease of the lower respiratory tract leading to
di¡use scarring of the lung parenchyma and end-stage
tissue ¢brosis (18,19). The histological features of IPF
usually comprise irregular thickening of the alveolar sep-
ta, relativelymild tissue in£ammation andpatchy areas of
heterogenous interstitial ¢brosis (20).The cause of IPF is
unknown andmany of the pathomechanisms are poorly
understood. Accumulation of in£ammatory cells, in par-
ticular neutrophils, in the alveolar space has been consis-
tently demonstrated in IPF, and the extent of
bronchoalveolar lavage neutrophilia seems to be linked
to the clinical severity of the disease.
This study was performed to compare sputum cells
and supernatant concentrations of MMP-9, TIMP-1 and
TNF in COPD and IPF patients bymeans of induced spu-
tum. Sputum induction is a reliable and safe, non-invasive
method to study components of the lower respiratory
tract. Its use in asthma and COPD is well established,
but it is also increasingly used to study in£ammation in
interstitial lung diseases (21,22).
METHODS
Patients
The studypopulation consisted of three groups: (a) 12 pa-
tients (75%males,mean age 64 years, range 56^73 years)
with moderate (stage 2) COPD according to criteria of
the Global Initiative for Obstructive Lung Disease
(GOLD) (23). All patients had negative skin-prick tests
to standard aeroallergens, a smoking history of at least
10 pack years, forced expiratory volumes in1s (FEV1)-va-
lues between 40% and 70% of predicted, a ratio of FEV1/
forced vital capacity (FEV1%FVC) of less than 70%, and
a post-bronchodilator reversibility of FEV1 o12%,
measured atbaseline15min after inhalation of a b-agonist
(Salbutamol MDI 400mg). None of the patients had
actively smoked for at least 6 months prior to the study,
receivedinhaledororal corticosteroids, orother systemic
drugs including theophylline, antibiotics or non-steroidal
anti-in£ammatorydrugs, or reported any acute exacerba-
tions for at least 4 weeks prior to sputum induction.
(b) Fifteen patients (68% males, mean age 59 years,
range 37^72 years) with a con¢rmed diagnosis of IPF ac-
cording to the ATS consensus report (24). All patients
with IPF were non-smokers at the time of evaluation.
Eleven IPF patientswere treatedwith oral steroids (med-
ian dose 32mg/day, range: 5^50mg/day), ¢ve received
immunosuppressants (four azathioprin, one cyclopho-sphamide), and four wereuntreated.Pulmonary function
tests in IPF patients revealed a mean total lung capacity
of 6074% predicted, and a di¡using capacity of 5776%
predicted.
(c) Fourteen healthy, non-smoking volunteers (56%
males, mean age 31 years, range 20^55 years) with nor-
mal lung function.
The study complied with local regulatory authorities,
all patientswere informed about the purpose of the spu-
tum induction and gave informedwritten consent.
SPUTUMINDUCTIONAND
PROCESSING
Sputum inductionwas performed according to amethod
previouslydescribed (25): patients inhaled3%hypertonic
saline delivered by an ultrasonic nebulizer device (Ultra-
Neb 2000, DeVilbiss, UK) for 15min. Patients were then
told to rinse their mouth, blow their nose and carefully
cough sputum into a Petri dish using forced expiratory
manouvres. If the induction was well tolerated, the ¢rst
portion of sputumwas discarded, and the inhalation pro-
cedure was repeated for another 15min. Lung function
was carefully monitored by spirometry every 5min dur-
ing induction to ascertain safetyof theprocedure. Induc-
tion was stopped, when a 420% drop in forced
expiratory volume in 1s (FEV1) occurred, and patients
were given two pu¡s of salbutamol (100mg/pu¡).
Sputum plugs were carefully seperated from salivary
secretions, and closely examined by light microscopy to
ascertain a least possible contamination of sputumwith
saliva and squamous cells. An appropiate sample was
then ¢lled into a1ml Eppendorf cup, weighed, andmixed
with twice its volume of dithiotreitol (DTT 0.1%, Calbio-
chem, Germany). Sputum was gently vortexed and
placed into a water-bath at 371C for 15min to allow
homogenization of the sample, with repeated mixing.
Then, phosphate-bu¡ered-saline (PBS, Gibco Life, Scot-
land) was added to achieve a10-fold dilution of the sam-
ple. Afterwards, samples were centrifuged at 400g for
10min.The supernatant was discarded and immediately
frozen at 201C for subsequent analysis. The cell pellet
was resuspended in 200^400ml PBSwith1% bovine ser-
um albumine (BSA, Sigma Chemicals,Germany).Twenty
micro grams of cell suspension was added to 5ml of try-
pan blue, vortexed, and 10ml of the solution then
counted in a Neubauer cell chamber. Viable cells were
counted, and the total cell count was calculated as cell
count per ml sputum.For cytospins, an adequate sample
of the cell suspension was added into a cytospin-tube to
achieve a total number of 20^30 000 cells per slide, spun
for 5min, ¢xated and stained with Hemacolor-staining
(Merck, Germany) to allow di¡erentiation of squamous
cells, macrophages, neutrophils, eosinophils, and
lymphocytes. Cytospin quality was regarded adequate
636 RESPIRATORYMEDICINEwhen contamination with squamous cells was less than
20%. Four hundred non-squamous cells were then inde-
pendently counted by two blinded observers. Relative
proportion of cell types was counted as percentage of
all non-squamous cells.
MEASUREMENTSOFMMP-9,TIMP-1,
ANDTNF
MMP-9, TIMP-1, and TNF in sputum supernatants were
measured by commercially available ELISAs (MMP-9 and
TIMP-1: Biotrak, Amersham Pharmacia, Germany, TNF:
R&DSystems,Abingdon,UK).The lowerdetection limits
of the assays were 4ng/ml for MMP-9, 3.125ng/ml for
TIMP-1, and 15.6pg/ml for TNF, respectively. MMP-9 and
TIMP-1 assays measured the total amount of free and
complexedMMP-9 and TIMP-1. All assayswere controlled
for the presence of 0.01%DTT in supernatant samples.
STATISTICALANALYSIS
Statistical analysis was performed using STATA 5.0 (Stata
Corp., Texas,USA) for personal computer.Unless other-
wise stated, data are given as mean values with standard
error of mean (7 SEM). Sputum total cells were log nor-
mally distributed in our patients, hence log cells were
used for analysis. Multiple group comparisons were per-
formedby analysis of variance followedby Student^New-
man^Keuls test. Correlations between data were
calculatedby Spearman’s rankcorrelation (rho). A P-value
of less than 0.05was considered as statistically signi¢cant.
RESULTS
Sputumcell counts and di¡erentials
Compared with healthy controls, only COPD patients
had elevated total sputum cells. Moreover, sputumTABLE 1. Sputumcells and soluble parameters in supernatanto
Data aremean7SEM COPD n=12
Log total cells, 106/ml 1.3570.3*
Neutrophils, % 6376*
Macrophages, % 3176*
Eosinophils, % 1.370.5
Lymphocytes, % 4.870.9
MMP-9, ng/ml 9147159**
TIMP-1, ng/ml 19497316*
MMP-9:TIMP-1ratio 0.8870.37**
TNF-alpha, pg/ml 69731
*Po0.05 vs. controls.
**Po0.05 vs.IPFand controls, respectively
(ANOVAfor three groups followedby Newman^Keuls).neutrophils were markedly increased both in COPD
and IPF (Table 1). Accordingly, the percentage of macro-
phageswas decreased in COPD and IPF. In general, there
were no di¡erences in sputum cell populations between
COPD and IPF patients.No di¡erences in theproportion
of lymphocytes and eosinophils were observed between
any of the three groups.This was also true, when the to-
tal number of each cell populationwas analyzed.
SPUTUMMMP-9 ANDTIMP-1LEVELS
Sputum MMP-9 levels were highest in COPD patients
comparedwith IPF and controls (Po0.001, both compar-
isons). SputumMMP-9 was also higher in IPF than in con-
trols, but this observation did not reach statistical
signi¢cance (P=0.09) (Table1).
SputumTIMP-1was also elevated in COPD and IPF pa-
tients compared with healthy controls (Po0.01, both
comparisons).Finally, theMMP-9:TIMP-1ratiowas signi¢-
cantly higher in COPD patients than in those with IPF
and controls (Po0.001, both comparisons).
SPUTUMLEVELSOF TNF
Sputum levels of TNF were similar in all three groups
(P40.2, all comparisons).
CORRELATIONOFSPUTUM
PROTEASESWITHCELLS,TNFAND
PULMONARYFUNCTIONINCOPD
ANDIPFPATIENTS
There was a positive correlation of sputum MMP-9 with
sputum neutrophils in all subjects (rho=0.68,
Po0.0001)(Fig. 1). The strongest correlation of MMP-9
and neutrophils was seen in COPD (rho=0.71, P=0.009),
whereas the correlation was weak in IPF patients, andf COPD (n=12),IPF patients (n=15) andhealthycontrols (n=14)
IPFn=15 Controls n=14
1.2170.22 0.670.2
6076* 2273
3476* 7373
1.170.6 0.470.2
6.572.1 5.271
238730 44728
15037212* 4577189
0.2370.06 0.0670.04
61712 111747
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There was also a strong correlation of MMP-9 and spu-
tumTNF in COPD patients (rho=0.76, P=0.004)(Fig. 2),
but not in IPF or healthy subjects (P40.5, both correla-
tions).
MMP-9 concentrations were negatively correlated
with airway obstruction (FEV1%FVC) in COPD
(rho=0.62, P=0.03), but there was no correlation of
MMP-9 with predicted values of di¡usion capacity
(rho=0.06, P=0.85), or vital capacity (rho=0.3,
P=0.29) in IPF.
DISCUSSION
COPD and IPF are chronic in£ammatorydisorders of the
respiratory system characterized by excessive matrix
degradation and tissue ¢brosis. Clinical phenotypes of
COPD and IPF, however, are largely distinguished byFIG. 1. Correlation of sputum neutrophils (%) and sputum
MMP-9 (ng/ml) in healthy subjects (=closed circles), IPF patients
(open squares) and COPD patients (closed triangles).The overall
correlation of pooledvalueswasrho=0.68, Po0.0001.
FIG. 2. Correlation of sputumMMP-9 (ng/ml) and sputumTNF
(pg/ml) in COPD patients.Rho=0.76, P=0.004.air£ow limitation, destruction of alveolar septa and pul-
monaryemphysema in COPD andparenchymal scarring,
alveolar wall thickening and restrictive lung function im-
pairment in IPF. In the present study, we have shown that
both COPD and IPF are characterized by increased pre-
sence of neutrophils, MMP-9 and TIMP-1 in respiratory
secretions sampled by induced sputum.
Despite these principal similarities, the distinct
pathologies of both diseases are also re£ected by di¡er-
ences in the relation of sputum MMP-9 and TIMP-1, since
the molar MMP-9:TIMP-1 ratio was dramatically in-
creased in COPD, whereas IPF patients showed a predo-
minant elevation of sputumTIMP-1.The predominance of
TIMP-1 over MMP-9 in IPF compared to COPD is sup-
ported by data from a series of other investigations. Ex-
cessiveTIMP-1expression has also been demonstrated in
skin lesion from scleroderma patients, (26) a disease
characterized by progressive connective tissue scarring,
and often accompanied by a pulmonary ¢brosis undistin-
guishable from sole IPF. Moreover, a predominance of
TIMPs over MMPs has also been previously reported in
IPF biopsies, and the authors have therefore character-
ized IPF as ¢broproliferative disorder with a prevailing
‘‘non-degrading’’ scar tissue (27).
Obviously, interpretation of data frominduced sputum
in IPF are limited by the fact, that induced sputum con-
tains mainly secretory products of mid-sized and small
conducting airways, which are therefore not fully repre-
sentative for the anatomic sites a¡ected by IPF (28).
However, several observations support the hypothesis
that distinct features of IPF are also represented in bron-
chial secretions of a¡ected patients, which can be as-
sessed by induced sputum. Most importantly, biopsy
studies in IPF have found a MMP:TIMP balance similar to
the one in our study with induced sputum (27). More-
over, histopathological studies have con¢rmed airway in-
volvement in the in£ammatory process of IPF (29).We
have also shown previously, that the degree of antioxi-
dant depletion (glutathione) in IPF can also be assessed
by induced sputum (30). And ¢nally, data from lung trans-
plant recipients with chronic rejection clearly indicate,
that there is agreement between bronchoalveolaer la-
vage (31,32) and induced sputum¢ndings (25)with regard
to neutrophilia.Despite the obvious di¡erences with re-
gard to a¡ected anatomic sites, the predominance of
TIMP-1overMMP-9 in sputa of IPF patients in comparison
to COPD would therefore nevertheless support the
concept of a ‘‘non-degrading’’ scar tissue in IPF.
This study also demonstrates high concentrations of
MMP-9 and TIMP-1 in the airways of COPD patients.
The sputum concentrations of MMP-9 and TIMP-1 in
COPD exceeded the concentrations observed in other
studies (11,33) andpossibly re£ect the pronounced sever-
ity of airway in£ammation in our patients, who had stage
2 (moderately severe) COPD. In a recent study byTanaka
and colleagues (11), in acute asthma exacerbations the
638 RESPIRATORYMEDICINEsputum MMP-9:TIMP-1 ratio ranged from 0.08 to 1.8,
which is very similar to the levels of stable COPD pa-
tients in our study.
Sputum MMP-9 levels were also correlated with the
severity of airway obstruction in COPD patients. This
observation stands in line with results from asthma stu-
dies, that have found a clear correlation of MMP-9 and
the MMP-9:TIMP-1 ratio with FEV1 in these patients
(10,11). Therefore, the forementioned data suggest, that
increased matrix turnover and an imbalance of MMP-9
withTIMP-1, is involved in thepathogenesis of airway ob-
struction in COPD.
In this study, MMP-9 levels were positively correlated
with sputum neutrophils.Given the pronounced sputum
neutrophilia in COPD and IPF patients, it is tempting to
speculate that neutrophils are themajor source of MMP-
9 in the airways of these patients, although therewas no
clear correlation in IPF.However, since we have not per-
formed staining of neutrophils for MMP-9 or measured
neutrophil secretion of MMP-9, this question cannot be
answered su⁄ciently by the data from our study.
Furthermore, sputum MMP-9 levels were also corre-
latedwith sputumTNF levels in COPD patients, suggest-
ing a regulatory role of TNF on MMP-9 secretion in this
group. These data stand in line with those of other
authors, who have reported a TNF-mediated induction
of MMP-9 synthesis and release by neutrophils (2). On
the other hand, MMP-9 could increase sputum levels of
TNF through proteolytic cleavage of membrane-bound
TNF precursors (34,35).
The source of airwayTIMP-1 in our patients remains
unclear, since there was no correlation of sputumTIMP-
1 with any sputum cell population. Possible sources of
TIMP-1could be cellular components of the extracellular
matrix, like ¢broblasts ormyo¢broblasts (36), or epithe-
lial cells.
The data on sputum MMP-9 in our study population
are clearly limited by the fact, that we have not per-
formed further assays to con¢rm theproteolytic activity
of MMP-9, e.g. zymography. Although themere presence
of MMP-9 does not necessarily indicate increased pro-
teolytic activity,most studies onMMP-9 in either sputum
or BAL have found a reasonable correlation between
MMP-9 levels and proteolytic activity. In particular,Tana-
ka and colleagues found a decrease in sputum MMP-9
during treatment of acute asthma, which was accompa-
nied by a decrasing gelatinolytic activity (11). Therefore,
we believe that this limitation of our study does not af-
fect our basic ¢ndings.
In conclusion, this studyreports onhigh levels ofMMP-
9 and TIMP-1in airway secretions of patientswith COPD
and IPF, with signi¢cant di¡erences regarding the MMP-
9:TIMP-1 ratio. To our knowledge, this is the ¢rst study
that has used induced sputum to characterize protease/
antiprotease imbalance in IPF. Our data support that
MMP-9 and TIMP-1 imbalance are involved in the patho-genesis of both COPD and IPF, with a predominace of
TIMP-1 over MMP-9 in IPF. The data also suggest, that
TNF may be involved in the control of MMP-9 in COPD,
and that the major source of MMP-9 in COPD are neu-
trophils.Therefore targeting the neutrophil or ^ derived
mediators inCOPDmayo¡er a future anti-in£ammatory
treatment, whereas the mechanisms involved in IPF, at
least with regard to MMP-9 and TIMP-1, seem to be dis-
tinct.
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